Explain this page
Arphra AIPlain-English read on Oruka Therapeutics, Inc.’s valuation06-10today
- Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?6d
- Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Trade8d
- Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update36d
- Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update36d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$7.34
-89.94% vs spot
Recommendation
Sell
3 of 3 methods
Method spread
0bull3bear
±5% threshold
Analyst PT consensus: $149.50 (+105.02%)
Candlestick · 1Y
Open in chart workstation →ORKA
68.86+100.76%H 71.72L 31.00MA50 52.67MA200 —Avg vol 864K
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.90% | +6.76% | +25.02% | +78.77% | +159.10% | +140.64% | +508.83% | +188.06% | +68.37% | -88.15% | -100.00% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$1.22M
10 txns
Net flow
−$1.22M
Aftermarket
LiveLast trade
$72.94
50 sh
Bid
$72.87
94 sh
Ask
$91.36
15 sh
Spread
$18.490
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 Dec 2025 | $0 | -$29.58M | $-0.54 |
| Q3 Sep 2025 | $0 | -$30.28M | $-0.69 |
| Q2 Jun 2025 | $0 | -$24.57M | $-0.58 |
| Q1 Mar 2025 | $0 | -$21M | $-0.50 |
| Q4 Dec 2024 | $0 | -$33.39M | $-1.54 |
| Q3 Sep 2024 | $0 | -$28.62M | $-1.91 |
Sector & industry today
LiveSectors
- Technology+2.35%
- Communication Services+2.08%
- Utilities+0.27%
- Consumer Cyclical+0.18%
- Consumer Defensive-0.26%
- Energy-0.56%
- Industrials-0.66%
- Basic Materials-0.75%
- Real Estate-1.02%
- Financial Services-1.16%
- Healthcare-1.35%
Top industries (issuer's industry highlighted)
- Biotechnology-3.11%
- Business Equipment & Supplies+6.20%
- Electronic Gaming & Multimedia+6.04%
- Semiconductors+4.84%
- Medical - Equipment & Services+4.78%
- Grocery Stores-4.22%
- Other Precious Metals-4.12%
- Internet Content & Information+3.79%
- Financial - Mortgages+3.64%
- Advertising Agencies-3.26%
- Oil & Gas Drilling-3.01%
- Gold-2.95%
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Oruka Therapeutics, Inc. (ORKA) Upgraded to Buy: What Does It Mean for the Stock?zacks.com·Jun 12, 2026
- Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to Tradezacks.com·Jun 10, 2026
- Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updateglobenewswire.com·May 13, 2026
- Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updateglobenewswire.com·May 13, 2026
Recent analyst activity
DB- Jun 03, 2026GradeBuy → BuyH.C. Wainwright Reiterates Buy Rating on Oruka Therapeutics (ORKA)H.C. Wainwright
- Jun 02, 2026GradeOverweight → OverweightPiper Sandler on Oruka Therapeutics (ORKA): 'We remain bullish into a catalyst-rich year+'Piper Sandler
- Jun 02, 2026PT$180.00Piper Sandler on Oruka Therapeutics (ORKA): 'We remain bullish into a catalyst-rich year+'Piper Sandler
Peers
No peer list available for ORKA.
Total assets
$488.62M
Total debt
$1.93M
Cash & equiv
$46.94M
Operating CF
-$88.21M
Free cash flow
-$88.42M
Buybacks
$0
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Sandler Laura Lee officer: Chief Operating Officer | Sell | 600 | $41.81K | Jun 15, 2026 |
Goncalves Joana officer: Chief Medical Officer | Sell | 300 | $21.19K | Jun 15, 2026 |
Goncalves Joana officer: Chief Medical Officer | Sell | 947 | $66K | Jun 15, 2026 |
Goncalves Joana officer: Chief Medical Officer | Sell | 1,636 | $111.88K | Jun 15, 2026 |
Goncalves Joana officer: Chief Medical Officer | Sell | 5,064 | $351.55K | Jun 15, 2026 |
Klein Lawrence Otto director, officer: Chief Executive Officer | Sell | 1,729 | $120.49K | Jun 15, 2026 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $0 | -$122.05M | -$105.43M | $-2.31 | — |
| FY 2024 | $0 | -$88.12M | -$83.72M | $-4.99 | — |
| FY 2023 | $0 | -$7.3M | -$5.34M | $-4.44 | — |
| FY 2022 | $0 | -$9.84M | -$9.93M | $-8.27 | — |
| FY 2021 | $0 | -$19.34M | -$19.32M | $-16.68 | — |